Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for Karyopharm Therapeutics in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($0.24) per share for the quarter, up from their previous estimate of ($0.31). The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($0.95) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics' FY2025 earnings at ($0.66) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the company posted ($0.30) earnings per share.

KPTI has been the topic of a number of other research reports. Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating for the company in a research report on Wednesday, August 7th. Royal Bank of Canada restated an "outperform" rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, StockNews.com lowered Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $0.88. 978,610 shares of the company were exchanged, compared to its average volume of 1,268,307. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company has a market capitalization of $109.32 million, a P/E ratio of -0.74 and a beta of 0.16. The business's 50 day simple moving average is $0.81 and its two-hundred day simple moving average is $0.91.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of KPTI. GSA Capital Partners LLP increased its holdings in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. AQR Capital Management LLC increased its stake in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after acquiring an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth about $494,000. Ikarian Capital LLC raised its holdings in shares of Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company's stock worth $618,000 after purchasing an additional 9,355 shares during the period. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after purchasing an additional 56,613 shares in the last quarter. Hedge funds and other institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).